作者: Janet L. Brandsma , Mark Shlyankevich , Linda Buonocore , Anjeanette Roberts , Steven M. Becker
DOI: 10.1016/J.VACCINE.2006.08.012
关键词:
摘要: Millions of people worldwide are currently infected with human papillomaviruses (HPVs). A therapeutic HPV vaccine would have widespread applicability because HPV-associated lesions difficult to treat and may progress carcinoma. We developed three attenuated VSV recombinants expressing the cottontail rabbit papillomavirus (CRPV) early protein E6 for use as vaccines. In cultured cells, two vectors expressed different levels protein, one a ubiquitin-E6 fusion protein. All were tested efficacy in (CRPV)-rabbit model. Mock vaccination had no effect on papilloma growth. contrast, inoculation any VSV-E6 vaccines reduced rate growth little 24% controls. five experiments, these effects achieved after single immunization. Furthermore, complete regression occurred some rabbits observed 4 months. VSV-based could significant advantages over other candidates described date.